메뉴 건너뛰기




Volumn 89, Issue 6, 2011, Pages 773-776

Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

EID: 79956329654     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.65     Document Type: Review
Times cited : (9)

References (10)
  • 1
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
    • (2007) New England Journal of Medicine , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 2
    • 35848930559 scopus 로고    scopus 로고
    • Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    • Diamond, G.A., Bax, L. & Kaul, S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147, 578-581 (2007). (Pubitemid 351664507)
    • (2007) Annals of Internal Medicine , vol.147 , Issue.8 , pp. 578-581
    • Diamond, G.A.1    Bax, L.2    Kaul, S.3
  • 4
    • 77950903574 scopus 로고    scopus 로고
    • Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation
    • Kaul, S. et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J. Am. Coll. Cardiol. 55, 1885-1894 (2010).
    • (2010) J. Am. Coll. Cardiol. , vol.55 , pp. 1885-1894
    • Kaul, S.1
  • 5
    • 77955285732 scopus 로고    scopus 로고
    • Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    • Nissen, S.E. & Wolski, K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
    • (2010) Arch. Intern. Med. , vol.170 , pp. 1191-1201
    • Nissen, S.E.1    Wolski, K.2
  • 6
    • 78649417401 scopus 로고    scopus 로고
    • Breaking news! Rosiglitazone and cardiovascular risk
    • Kaul, S. & Diamond, G.A. Breaking news! Rosiglitazone and cardiovascular risk. Nat. Rev. Cardiol. 7, 670-672 (2010).
    • (2010) Nat. Rev. Cardiol. , vol.7 , pp. 670-672
    • Kaul, S.1    Diamond, G.A.2
  • 7
    • 79251569565 scopus 로고    scopus 로고
    • Analytical issues regarding rosiglitazone meta-analysis
    • Claggett, B. & Wei, L-J. Analytical issues regarding rosiglitazone meta-analysis. Arch. Intern. Med. 171, 179-180 (2011).
    • (2011) Arch. Intern. Med. , vol.171 , pp. 179-180
    • Claggett, B.1    Wei, L.-J.2
  • 9
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, Stroke, Heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham, D.J. et al. Risk of acute myocardial infarction, Stroke, Heart failure, And death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411- 418 (2010).
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1
  • 10
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan, D.M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009).
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.